News >

Paradigm Evolving in HER2+ Breast Cancer With CNS Mets

Kristi Rosa
Published: Tuesday, Dec 11, 2018

Shannon L. Puhalla, MD

Shannon L. Puhalla, MD

Central nervous system (CNS) metastases remain challenging to treat in patients with breast cancer, and incidence and outcomes have been found to vary depending on subtypes of the disease.

State of the Science Summit™ on Breast Cancer, Puhalla, an oncologist at the University of Pittsburgh Medical Center, discussed some of the advances being made in systemic treatment for patients with brain metastases from breast cancer.

OncLive: What are the key takeaways from your presentation on brain metastases in breast cancer?

Puhalla: Part of what is important to know is, historically, how often do brain metastases from breast cancer happen? What are the differences among the different subtypes? Are there differences among HER2-positive brain metastases compared with TNBC brain metastases compared with estrogen receptor [ER]–positive brain metastases? The short answer is, “There are.”
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x